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Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the USA,
accounting for,40,000 deaths annually. The dismal prognosis for PDAC is largely due to its late diagnosis.
Currently, the most sensitive diagnosis of PDAC requires invasive procedures, such as endoscopic
ultrasonography, which has inherent risks and accuracy that is highly operator dependent. Here we took
advantage of a general characteristic of solid tumors, the acidic microenvironment that is generated as a
by-product of metabolism, to develop a novel approach of using pH (Low) Insertion Peptides (pHLIPs) for
imaging of PDAC. We show that fluorescently labeled pHLIPs can localize and specifically detect PDAC in
human xenografts as well as PDAC and PanIN lesions in genetically engineered mouse models. This novel
approach may improve detection, differential diagnosis and staging of PDAC.
A
pproximately 45,000 Americans are diagnosed with pancreatic ductal adenocarcinoma (PDAC) each year
and the incidences of PDAC are rising1. Unfortunately, there has been little progress in the outcomes of
patients with PDAC since the 1970s. Surgical resection is the mainstay of therapy; however, only 20% of
patients are eligible for resection due to the presence of advanced disease at the time of diagnosis2. The lack
of specific symptoms (due to the physical position of the organ), and the lack of sensitive and specific biomarkers,
make obtaining a diagnosis difficult at an early stage3. For these reasons, there is an urgent need for tools to aid in
the early and specific detection of PDAC prior to the development of micro-metastatic disease. To date the most
commonly used modalities for diagnosing PDAC, including computed tomography (CT), magnetic resonance
imaging (MRI) and endoscopic ultrasonography (EUS), are unable to detect early lesions and are mainly used for
disease staging3,4.
In the current study, instead of employing a traditional molecular targeting strategy based on imaging of a
single biomarker protein overexpressed in a subset of cancer cells, we evaluated a more general approach for
targeting: the acidity of the tumor microenvironment. Acidosis is generated as a by-product of cancer cell
metabolism and it is correlated with tumor development and progression5–7. Imaging the acidic microenviron-
ment avoids the common problem of heterogeneity of protein biomarkers, which limits the usefulness of agents
directed to specific cell surface markers8,9. We employed recently developed pH-sensitive probes, pH (low)
insertion peptides (pHLIPsH) to image PDAC inmice. The pHLIPs are water-soluble membrane peptides, which
insert into the lipid bilayer of membranes and form transmembrane helix only within an acidic extracellular
microenvironment, such as that found in tumors10–13. We show that the fluorescently-labeled pHLIP probes
detected PDAC tumors, metastasis and PanIN lesions in preclinical mouse models of PDAC. The obtained data
provide critical proof of principle supporting further development of this novel approach, which will ultimately
lead to a clinical breakthrough for early detection and diagnosis of PDAC.
Results
The goal of our study is to demonstrate the feasibility of targeting the extracellular acidity for imaging PDAC in
different tumor models. To achieve this goal we used pH-sensitive WT-pHLIP peptide and its control, 2K-WT-
pHLIP (Table 1) which have been well validated in other tumor models13–17. The protonatable Asp residues in
transmembrane (TM) part of the 2K-WT-pHLIP are replaced by the positively charged non-protonatable Lys
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residues, which reduces pH-dependent ability of the 2K-WT-pHLIP
to insert into membrane. In addition, we investigated targeting of
PDACwith pHLIP variants, Var3 andVar7 (see Table 1) as they have
recently been identified as novel variants that are suited very well for
imaging of acidic tumors12. All peptides contain single Cys residue at
the non-inserting into membrane termini (Table 1), which was con-
jugated with Alexa546 or Alexa647 fluorescent dyes. The constructs
were purified and used in in vivo and ex vivo fluorescent studies.
pHLIP targets PDAC and peritonealmetastasis in human pancreatic
cancer xenografts. To test if tumor acidity could serve to detect
primary tumors, we used an orthotopic mouse model of PDAC in
which human PDAC cells tagged with luciferase were injected
directly into the pancreas and tumor growth was monitored
weekly via bio-luminescence imaging. Once tumors were formed
(Figure 1A) animals were injected with 40 mM of WT-pHLIP via
tail vein. We compared whole body fluorescence imaging signals of
mice with tumors injected with probe (tumor 1WT-pHLIP), with
Table 1 | Sequences of pHLIP peptides used in the study. The trans-
membrane (TM) sequences of the peptides are shown in bold
Variant ID Sequence
WT-pHLIP ACEQNPIY WARYADWLFTTPLLLLDLALLV DADEG
2K-WT-pHLIP ACEQNPIY WARYAKWLFTTPLLLLKLALLV DADEG
Var3-pHLIP ACDDQNP WRAYLDLLFPTDTLLLDLLW
Var7-pHLIP ACEEQNP WARYLEWLFPTETLLLEL
Figure 1 | pH-sensitive probes efficiently detect human pancreatic cancer xenografts. Representative in vivo bioluminescent (A) and fluorescent (B)
images of athymic nude mice without tumor (normal; n 5 5; left) and with tumor (orthotopic model of PDAC with luciferase-labeled Capan-2 cells;
n 5 5) injected with 40 mM of Alexa647-WT-pHLIP in 100 ml of PBS. Tumor and kidneys are indicated by black and blue arrows, respectively.
Representative ex vivo images of normal pancreas and PDAC frommice injected with Alexa647-WT-pHLIP (C). Ex vivo bioluminescent and fluorescence
signal quantification of pancreas (n 5 5 per group) (D) and fluorescence signal quantification of liver, kidney and lung (E–G). Values are means 6 SEM,
*p 5 0.0167, **p 5 0.0025.
www.nature.com/scientificreports
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mice containing tumors but not injected with probe (tumor –WT-
pHLIP) and control mice without tumors injected with probe
(normal 1WT-pHLIP; Figure 1). We found that the fluorescence
emitted after 24 hrs of injection was localized mostly in the kidney
and PDAC (Figure 1B). The time point of 24 hrs post-injection was
selected based on the results of our previous findings, which indicate
that the initial blood uptake is typically 45% ID/g decreasing steadily
to 1–3% ID/g at 24 hrs post injection14,15. The metabolism data
showed that WT-pHLIP consisting all of D-amino acids remains
intact in the blood of living rats up to at least 1 hr post injection,
which is enough time frame for tumor targeting. The slow clearance
profile is due to the interaction (no insertion) of pHLIP with cellular
membranes at neutral pH. The constructs are retained in tumors for
at least 2 days when pHLIP is inserted into cellular membranes at
low extracellular pH.
Ex-vivo examination of the pancreas from mice with and without
tumors indicates the WT-pHLIP probe specifically targets to the
tumor-bearing pancreas, but not normal pancreas (Figure 1C, D).
The fluorescent signal in pancreases of mice bearing tumor was 13.6
times higher (p 5 0.0025) than fluorescence in normal pancreas
(Supplementary Table 1). Signals from liver, kidney, and lung were
also quantified (Figure 1E–G and Supplementary Table 1).
Interestingly, the signal in the kidney at 24 hrs after WT-pHLIP
administration was significantly higher in mice bearing tumors than
in non-bearing tumor mice (Figure 1E). Moreover, to determine if
acidosis could be used as a marker to detect metastases, mice with
detectable metastasis via luminescence signal (Figure 2A) were
injected with fluorescently labeledWT-pHLIP. After 24 hrs of probe
injection, the fluorescence of WT-pHLIP from primary tumor and
all peritoneal metastasis were co-localized with the luminescence
signal (Figure 2).
pHLIPs act in a pH dependent manner to detect PDAC andmeta-
stasis in genetically engineeredmousemodels (GEMMs) and early
PanIN lesions. To verify our findings of acidosis as a marker for
imaging primary PDAC and metastasis in an autochthonous model
of PDAC, the ability ofWT-pHLIP probe to image tumors developed
in well-established GEMMs was tested18,19. Similar to the orthotopic
model, we found that WT-pHLIP targets PDAC and liver metastasis
(Figure 3A) in a GEMM, and demonstrates the strongest signal
compared to other organs (Figure 3B–E and Supplementary Table
2). The fluorescent signal in pancreases of mice bearing tumor was
17.6 times higher (p5 0.0043) than fluorescence in normal pancreas.
Moreover, to test if PDAC and metastasis pHLIP targeting was pH
dependent, the animals were injected with the control pH-insensitive
probe, 2K-WT-pHLIP. Indeed the fluorescence signals detected in
the mouse tissues are pH-dependent as the signals from PDAC and
kidney are significantly reduced in mice injected with 2K-WT-
pHLIP compared to WT-pHLIP (Figure 3B–F and Supplementary
Table 2). Similar to the orthotopic model, the signal in the kidney at
24 hrs after WT-pHLIP administration was significantly higher in
tumor-bearing mice than in non-bearing tumor mice (Figure 3C).
Histologic evaluation of pancreas from PDAC mice injected with
WT-pHLIP show a significant increase in the fluorescence com-
pared to normal pancreas injected with WT-pHLIP (Figure 4).
The ability to detect PDAC at an early stage is of great clinical
necessity and significance. Therefore, we tested the ability of WT-
pHLIP to target pre-malignant and early stage PDAC by imaging
mice with PanIN lesions. The fluorescent signal from the mice with
PDACwas the strongest compared to mice with pancreas containing
early PanIN lesions (Figure 5A–B). At the same time, we observed a
statistically significant 9.2 times increase (p 5 0.0357) in fluor-
escence signal from the mice pancreas containing PanIN lesions
compared to control mice pancreas (Figure 5 and Supplementary
Table 3).
Finally, we tested performance of recently identified new pHLIP
variants such as Var3 and Var7. Targeting for both pHLIP variants
was pH-dependent (Figure 6 and Supplementary Table 4) similar to
WT-pHLIP. The fluorescent signal in pancreases targeted by Var3
and Var7 of mice bearing tumor was 12.4 (p 5 0.0003) and 22.8 (p 5
0.0043) times higher than fluorescence in normal pancreas,
respectively.
Discussion
Targeting and imaging of tumor acidity is an attractive strategy,
given that acidity is a general property of the tumor microenviron-
ment that is less likely to be subject to tumor resistance and selection.
Acidity as a universal marker for tumor targeting is associated with
tumor development due to a combination of factors, like hypoxia,
glucose uptake and carbonic anhydrase activity5–7. Rapid cell growth
and an inadequate blood supply produce hypoxic conditions that
cause a partial use of glycolysis in tumor cells, resulting in acidifica-
tion of the cytosol, to which the cell adjusts by pumping protons into
the external environment. However, hypoxia and low blood supply
are not the only mechanisms responsible for the development of an
acidic environment within solid tumors20.Malignant cancers have an
elevated glucose uptake even under normal oxygen conditions, over-
whelming the mitochondrial capacity and using glycolysis for the
overflow. This condition is known as ‘‘aerobic glycolysis’’ or the
Warburg effect21. Cells exhibiting aWarburg effect catabolize glucose
at a high rate6,22, and the use of glycolysis results in much higher level
of protons and lactic acid, which are pumped across the cell plasma
Figure 2 | pH-sensitive probes detect primary tumors and metastasis in
human pancreatic cancer xenografts. Orthotopic model of PDAC with
luciferase-labeled Capan-2 cells injected with 40 mM of Alexa647-WT-
pHLIP in 100 ml of PBS (1pHLIP; n5 5) Bioluminescent signal indicating
tumor growth and metastasis (A) co-localizes with the fluorescent signal
demonstrating pH-dependent targeting by Alexa647-WT-pHLIP (B). The
overlay of the signals are shown on (C).
www.nature.com/scientificreports
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membrane into the extracellular space, where they accumulate in
poorly perfused regions23–25. In addition to the lactic acid-output,
expression of carbonic anhydrases 9/12 on the tumor cell surface
catalyzes the extracellular trapping of acid by hydrating cell-gener-
ated CO2 into HCO32 and H126,27. These mechanisms in combina-
tion create an acidic extracellular milieu favoring tumor growth,
invasion and development. Moreover, the extracellular pH of solid
tumors plays a role in almost all steps of metastasis, and acidic
tumors become highly aggressive and metastatic28.
The Warburg effect and altered metabolic pathways has been
reported in PDAC supporting the targeting of acidosis for this
tumors29–31. Therefore, in present study, we used pH-sensitive
Figure 3 | Probes act in a pH dependent manner to detect PDAC and metastasis in GEMMs. GEMM with normal pancreas (non-tumor bearing
mice; n5 10) or PDAC (tumor bearing mice; n5 10) were injected via the tail vein with 40 mMof Alexa546-WT-pHLIP in 100 ml of PBS (n5 5) or with
40 mM of Alexa546-2K-WT-pHLIP (peptide sequence modified to be less sensitive to pH) in 100 ml of PBS (n 5 5). (A) Representative ex vivo
fluorescence images of pancreas, kidney, liver and lung of non-tumor bearing mice (left) and tumor bearing mice (right) 24 hrs after Alexa546-WT-
pHLIP injection. Liver metastases were visualized in some mice (square) which correlated with an increase in fluorescent signal. (B–E) Ex vivo
fluorescence quantification of non-tumor bearing mice (n 5 10) and tumor bearing mice (n 5 10) injected with Alexa546-WT-pHLIP or Alexa546-2K-
WT-pHLIP. (F) Comparison of tumor targeting by Alexa546-WT-pHLIP and Alexa546-2K-WT-pHLIP (control). Values are means 6 SEM,
*p 5 0.0159, **p 5 0.0043.
www.nature.com/scientificreports
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pHLIP probes labeled with fluorescent Alexa dyes to evaluate their
ability to detect PDAC. We have shown that WT-pHLIP targets
primary tumor, peritoneal and liver metastasis with high accuracy.
The fluorescent signal in pancreases of mice bearing tumor is 13–17
times higher than the fluorescence in normal pancreas injected with
pHLIP. The targeting is pH-dependent, as a pH-insensitive control
pHLIP probe (2K-WT-pHLIP) shows significantly less accumula-
tion in acidic tumors and kidney. Thus, pHLIP probes demonstrate
high specificity and sensitivity in targeting of pancreatic tumors. An
interesting finding of our study, whichmight have important clinical
relevance, is an enhanced fluorescence signal in the kidneys of tu-
mor bearing animals injected with pHLIP compared to non-tumor
bearing animals. It could be associated with the elevated acidity in the
kidneys of tumor bearing mice and might be used to monitor disease
in urine with clinical significance. Another important finding is the
ability of pHLIP to target PDAC in its early stages (PanIN lesions).
Importantly, normal pancreas does not accumulate WT-pHLIP,
making it a sensitive and specific test for the diagnosis of early stage
PDAC. These are significant findings for the development of imaging
protocols to detect early neoplastic transformations from normal
pancreas in order to increase the odds of detecting this deadly disease
at an early stage. In addition to WT-pHLIP, we tested two other
pHLIP variants: Var3 and Var7. The latest one, Var7 shows fast
blood clearance in xenograft models of lung and cervical cancer12
suggesting that it may be the best probe for PET (positron emission
tomography) and SPECT (single photon emission computed
tomography) imaging. Indeed, we observed 23 times increase of
fluorescence signal in pancreases of mice bearing tumor compared
to the fluorescence in pancreas of normal mice injected with Var7.
In summary, this work provides fundamental preclinical evidence
using various mouse models that targeting of tumor acidity in pan-
creas by the pH-sensitive pHLIP probes might be useful for the
clinical detection of PDAC. It opens an opportunity for the develop-
ment of novel imaging clinical protocols to improve detection, nar-
row the differential diagnosis and improve staging of PDAC. Other
use of this probe for surveillance of PDAC will help improve survival
as it will be able to detect most tumors in a resectable stage.
Methods
Conjugation of pHLIP Variants with Fluorescent Dyes. pHLIP variants were
prepared by solid-phase peptide synthesis using Fmoc (9-fluorenylmethyloxycarbonyl)
chemistry and purified by reverse phase chromatography at the W.M. Keck
Foundation Biotechnology Resource Laboratory at Yale. Each pHLIP variant was
conjugated with AlexaFluorH546 and AlexaFluorH647 C5-maleimide in DMSO at a
ratio of 151.2 of dye5peptide and incubated at room temperature for 4–8 hours.
The reaction progress was monitored by reverse phase HPLC. The products were
isolated via HPLC. Peak identity was confirmed by SELDI-TOF mass spectrometry
and analytical HPLC. The concentrations of the conjugated peptides were
determined by absorbance (for Alexa546: e 5 93,000 M21cm21; and for Alexa647:
e 5 265,000 M21cm21).
Cell Lines. An established pancreatic cancer cell line (Capan- 2) was obtained from
the American Type Culture Collection (ATCC, Manassas, VA). Cells were routinely
cultured in recommended media. All cells were maintained at 37uC in a humidified
atmosphere of 5% CO2.
Immunocytochemistry. Frozen tissue slides were covered using VECTASHIELD
mounting medium (Vector laboratories, Burlingame, CA). Sections were examined
on a Zeiss Axioplan2microscope and images captured with a Hamamatsu ORCA-ER
camera with Image-Pro Plus software (Media Cybernetics, Rockville, MD) and
analyzed using Simple PCI software (Hamamatsu Corporation, Sewickley, PA).
Animal models. To assess if pHLIP can serve as a biomarker for in vivo imaging,
studies were performed in human pancreatic cancer xenografts in immunodeficient
(acquired from The National Cancer Institute with age ranging from 5–6 weeks old)
and transgenic mice. Animals were housed at the MD Anderson Cancer Center
animal facility. All animal procedures were performed in accordance with the MD
Anderson Cancer Center (Houston, TX) institutional guidelines using an approved
animal protocol by the Institutional Animal Care and Use Committees of the
Figure 4 | pH-sensitive probes localize to PDAC and not normal pancreas in GEMMs. (A) H & E, fluorescence of Alexa647 (WT-pHLIP) and DAPI
(nuclei) signal of non-tumor bearing mice (top) and tumor bearing mice (bottom) treated with 40 mM of Alexa647-WT-pHLIP in 100 ml of PBS
(n 5 5). (B) Quantification of fluorescence signal relative to nuclei staining. Values are means 6 SEM, ****p , 0.0001.
www.nature.com/scientificreports
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University of Texas MD Anderson Cancer Center. Mice used for optical imaging
studies were fed with chlorophyll-free diet.
Genetic PanINs and PDAC mouse models were developed by crossing LSL-
KRasG12D mice32 with floxed p53 mice33 and pancreatic specific cre (Pdx-1-Cre)
mice34 to yield mice which possessed conditional p53 deletion and endogenous
levels of mutant KRasG12D 18. PDAC in this mice developed in 6–8 weeks after
birth35. Littermates without PDAC served as controls. Moreover, LSL-KRasG12D
mice32 were cross with elastase (Ela) tamoxifen-regulated CreERT (Ela-CreERT)
as described previously36 and fed a high-fat diet for 30 days to induce PanIN 1
lesions as previously describe19. LSL-KRasG12D, p53 floxed, and Pdx-1-Cre genetic
mice were obtained from the Mouse Models for Human Cancer Consortium
Repository (Rockville, MD).
Figure 5 | pHLIP can detect early PanIN lesions and tumors in GEMMs. Representative ex vivo fluorescence images of pancreas (A) and fluorescence
quantification of pancreas (B), kidney (C), liver (D) and lung (E) from non-tumor bearing mice (n5 10), tumor bearing mice (n5 10), mice containing
PanIN lesions (n 5 5) and mice with pancreatitis (n 5 5) which were injected with 40 mM of Alexa647-WT-pHLIP in 100 ml of PBS or 100 ml of PBS.
Values are means 6 SEM, *p , 0.0357, **p 5 0.0016.
Figure 6 | pHLIP variants can detect PDAC efficiently in GEMMs. Ex vivo fluorescence quantification of pancreas, kidney, liver and lung from non-
tumor bearing mice (n 5 10) and tumor bearing mice (n 5 10) injected with 40 mM of Alexa647-Var3-pHLIP (A) and Alexa546-Var7-pHLIP
(B) in 100 ml of PBS. Values are means 6 SEM, *p 5 0.02, **p , 0.0043, ***p 5 0.0003.
www.nature.com/scientificreports
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To establish orthotopic tumors, mice were anesthetized with a single intraperito-
neal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg) and then the pan-
creas was exposed through a left abdominal incision (laparotomy). Sub-confluent
Capan-2 cells (ATCC, Manassas, VA) labeled with firefly luciferase as per37 were
detached with 0.25% trypsin-EDTA and cell viability was assessed by trypan blue
exclusion. Capan-2 cells are one of the few PDAC cell lines that form a prominent
stromal reaction mimicking the human tumor. Cells (1.8 3 105) were resuspended in
50 mL of Hanks Balanced Salt Solution (HBSS) and directly injected into the pancreas
(caudal). After tumor implantation, the pancreas was carefully returned to the peri-
toneal cavity and the abdomen was closed. Tumor growth was assessed every week by
bioluminescence imaging for 8 weeks using a cryogenically cooled imaging system
coupled to a data acquisition computer running Living Image 4.3.1 software
(Xenogen/Caliper, Alameda, CA). Before imaging, animals were injected subcuta-
neously with 40 mg/mL of luciferin potassium salt in PBS at a dose of 150 mg/kg
body weight. Signal intensity was quantified as the sum of all detected photons within
the region of interest per second. Twomonths after tumor implantation, pH-sensitive
and control probes were injected via tail vein and imaged 24 hrs after injection.
Tissues were also fixed with formaldehyde or snap frozen in liquid nitrogen and
examined histologically.
In vivo and ex vivo Imaging. Animals were injected with a single dose of the
fluorescence pH-sensitive and controls probes (40 mM pHLIP/100 ml PBS) or 100 ml
PBS (controls without probe) intravenously through tail vein using a 30 gauge syringe
needle. After 24 hrs the anesthetizedmice were placed in the heated imaging platform
of IVIS-Spectrum optical imaging systems (Xenogen/Caliper, Mountain View, CA).
White light and near infrared fluorescence (NIRF) images were acquired sequentially
using fluorescence filters for Alexa546 and Alexa647. Mice were imaged 24 hrs post
probe intravenous injection.Mice were sacrificed and organs/tissues were excised and
rinsed with PBS then imaged for their associated NIRF. Fluorescence variations
between different organs/tissues were corrected by subtracting the auto-fluorescence
signals obtained from imaging organs/tissues of mice without any probe injected.
General illumination setting and image acquisition parameters were: epi-
illumination; 0.5 sec. exposure time; f/stop5 2; binning (HR) 4; field of view (FOV5
12.9 cm or 6.5 cm width and height). Luminescence each image was defined as
photons per second per centimeter squared per steradian (p/s/cm2/sr). Fluorescence
contrast, defined as radiance, was quantified using identical size regions of interest
(ROI).
Statistical analysis.Data are presented asmean6 SEM. For in vivo studies, we used 5
animals per group (n 5 5). Statistically significant differences were determined by
two-tailed unpaired Student’s t-test (P, 0.05 was taken as significant). When more
than 2 groupswere analyzed, ANOVAwas used to analyze the data and theNewman–
Keuls multiple comparison test was used to check the posttest significance. Statistical
significance was defined as P , 0.05.
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